Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St Jude gets US nod to add V-V (ventricle to ventricle) timing in CRT-Ds (cardiac resynchronisation therapy devices):

This article was originally published in Clinica

Executive Summary

The US FDA has given St Jude Medical approval to add V-V (ventricle to ventricle) timing to new models of its Epic HF and Atlas+ HF family of cardiac resynchronisation therapy devices (CRT-Ds). V-V timing refers to the delay between contraction of the left and right ventricles, compared with simultaneous pulses to both ventricles. St Jude's V-V timing allows physicians to adjust the delay between ventricular outputs, and choose which chamber is paced first. Patients who do not respond to simultaneous biventricular pacing systems may benefit from the sequential timing offered by V-V programmability, said the St Paul, Minnesota firm, which believes it is the first CRT-D supplier in the US to offer this expanded programmability.

You may also be interested in...

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.

AHPA Members Report Problems In Raw Material, Other Supplies In Pandemic Survey For USDA

Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.

COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues

Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts